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52,448) for MTX, U$ 93,992 (89,36698,982) for abatacept, and $73,100 (68,539
81,877) for infliximab. The total QALYs gained(discounted) by MTX, abatacept, and
infliximab during the same period were: 2.96 (2.893.03), 4.05 (3.854.30) and 3.26
(3.163.39) respectively. The Incremental Cost-Effectiveness Ratio was U$ 39,980
(36,64945,011) for Abatacept compared to MTX compared to U$ 77,790
(62,36998,124) per QALY gained with infliximab. CONCLUSIONS: The use of
abatacept is more costeffective than the use of infliximab, both compared to
MTX, in patients with Rheumatoid Arthritis with IR MTX in Venezuela.
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OBJECTIVES: Rheumatoid Arthrtis (RA) critically impair the quality of life of pa-
tients. Biologic treatments represent a therapeutic alternative for patients who
failed disease-modifying antirheumatic drugs. However, their high cost is a chal-
lenge for clinicians and decision makers. The aim of this study was to assess the
cost-effectiveness of biologic alternatives to treat RA currently available in Mexico,
froman institutional perspective.METHODS:Adecision-treemodelwas developed
to simulate the clinical course of patients treated with etanercept (reference treat-
ment), adalimumab, infliximab, tocilizumab or rituximab as first-line therapies, as
well as associated costs over one-year period. Therapy continuation or treatment
switch was evaluated at month 6. Effectiveness measures were: proportion of pa-
tients achieving 70% improvement in both, tender or swollen joint counts following
the American College of Rheumatology (ACR70) criteria and quality adjusted life
years gained (QALY=s). Costs considered included: biologics, concomitant drugs,
medical follow-up and side effects management. Clinical response of alternatives
was extracted from published literature, while costs were collected from Instituto
Mexicano del Seguro Social (IMSS) official databases. Probabilistic sensitivity anal-
yseswere done throughMonte Carlo Simulation second-order approach. RESULTS:
The effectiveness of therapies resulted in [ACR70, QALY=s]: etanercept [31.3%, 0.79];
adalimumab [18.1%, 0.77]; infliximab [12.8%, 0.73]; tocilizumab [21.1%, 0.77] and
rituximab [11.9%, 0.75]. Expectedmean costs per patient were: US$12,914.36 [95%CI
US$12,901.58-US$12,927.08]; US$15,715.06 [95%CI US$15,699.73-US$15,730.39];
US$14,479.96 [95%CI 14,465.77-US$14,494.16]; US$44,455.03 [95%CI US$44,411.53-
US$44,498.53] and US$17,267.61 [95%CI US$17,250-US$17,284.53], respectively. Et-
anercept is both, the less costly and the most effective alternative: US$31,504.80
less than tocilizumab (the most costly alternative) and 19.3% more patients meet
the ACR70 criteria regarding rituximab (the less effective alternative). Acceptability
curves showed that etanercept regardless willingness to pay would be the most
cost-effective biologic. CONCLUSIONS: Due to their lower costs and favorable ef-
fectiveness profile, etanercept is dominant over other biologic treatments in the
management of RA at IMSS.
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OBJECTIVES: Inappropriate analgesia in postoperative pain (POP) raises hospital-
ization costs and increases the burden of several surgeries with a meaningful im-
pact over patient’s quality of life. The objective of this study was to develop an
economic analysis to evaluate parecoxib, ketorolac andmorphine in the treatment
of POP in patients who underwent total hip arthroplasty from an institutional
perspective. METHODS: A cost-effectiveness analysis was developed using a
Bayesian decision-tree model, to simulate costs and effectiveness outcomes over
the postoperative hospitalization period (15 days). Comparators were multimodal
analgesics: morphine (52 mg/day) plus parecoxib (40 mg/day); morphine (52 mg/
day) plus ketorolac (90 mg/day) and morphine (57 mg/day) alone. Effectiveness
measures were: percentage of treatment response without adverse events (AE)
meeting the highest score of the patient’s global evaluation survey (excellent).
Effectiveness data and transition probabilities were collected from international
published literature. Resource use and cost data was gathered from hospital re-
cords of patients undergoing total hip arthroplasty at the Social Security Mexican
Institute (IMSS) (n89). The model was calibrated according to international phar-
macoeconomics guidelines. One-way and probabilistic sensitivity analyses were
performed with Monte Carlo Simulation second-order approach. RESULTS: Pa-
tients who received parecoxib exhibited 41% of treatment response, followed by
morphine (26%) and ketorolac (24%). Estimated costs per patient were lower with
parecoxib (US$ 5,439.30) followed by ketorolac (US$5,538.91) and morphine
(US$5,553.71). No statistical differences were found among the costs of analgesic
therapies (p0.05). Parecoxib showed a weak dominance against its competitors.
Acceptability curves showed parecoxib as themost cost-effective therapywith 95%
when willingness to pay is US$6,500. CONCLUSIONS: Results show that at the
IMSS, parecoxib is a cost-effective treatment that significantly reduces POP in pa-
tients who underwent total hip arthropasty. This information could be useful for
developing markets healthcare institutions in order to establish efficient analge-
sics improving current health outcomes.
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OBJECTIVES: The goal of this studywas to estimate the cost-effectiveness of stron-
tium ranelate in the treatment of postmenopausal osteoporotic women in Turkey.
METHODS: A validated Markov microsimulation model with a Turkish payer’s
perspective estimated the cost per quality-adjusted life-year (QALY) of strontium
ranelate treatment compared with risedronate, raloxifene, ibandronate, alendro-
nate and calcitonin. Markov Model was used and applied in the Treeage Pro soft-
ware over a cohort of 1000 patients in the pharmacoeconomical analysis. As for the
sensitivity analysis, theMonte Carlo Simulationwas used, applying a simulation of
10.000. Data on the effect of both treatments on fracture risk were taken from the
literature. The cost of the treatments were calculated based on Turkish reimburse-
ment systems, the indirect and intangible costs were omitted. The direct disease
costs include the amount spent for the costs associated with the outpatient, inpa-
tient, medical supplies, all the laboratory or imaging tests and the interventions
performed. The costs of the side effectswere added to all the drug costs. The official
product summaries were used for detecting the side effects of the products.
RESULTS: Strontium Ranelate provides the highest gain of quality life years and is
the superlative therapeutical choice with respect to QALY. According to it’s cost
and effectiveness value, strontium ranelate was dominant (i.e. more effective and
less costly) versus ibandronate and calcitonine for postmenopausal osteoporotic
women. The cost per QALY gained by strontium ranelate compared to ibandronate
was € 5582 and calcitonine was € 3943. Compared to alendronate, risedronate and
raloxifene, strontium ranelate was cost effective (i.e. more costly but more
effective).CONCLUSIONS:The results of this study suggest that strontium ranelate
is a cost-effective strategy, in a Turkish setting, for the treatment of postmeno-
pausal osteoporotic women.
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OBJECTIVES: Determine the costeffectiveness of abatacept or infliximab in pa-
tients with rheumatoid arthritis (RA) with inadequate response to methotrexate
(IRMTX) in Colombia. METHODS: Dynamic simulation techniques from a previ-
ously validatedmodel and clinical data from published literature were used for the
analysis. The functional disability was assessed using the Health Assessment
Questionnaire (HAQ). A HAQ score was randomly assigned pretreatment based
on the prevalence of the disease and the demographic characteristics for Colombia,
then projected over time using the efficacy results from published trials. Direct
medical costs were calculated from private and public hospitals,and the informa-
tion system of the Ministry of Social Protection (SISMED) and validated with local
experts (Exchange rate: $1,920 Colombian peso1 US Dollar). A 10year time ho-
rizon and the payer’s perspective were assumed. Costs and health outcomes were
discounted at 3% annually. Univariate and probabilistic sensitivity analyses were
performed to assess the robustness of the results of the model. RESULTS: In a
hypothetical cohort of 1,000 patients with RA  IR MTX, the costs of treatmentfor
the first year for MTX were U$794 dollars, compared to U$16,659 for abatacept and
U$17,531 for infliximab, assuming dosages for average patients below 60 kg. Addi-
tional analysis with patients over 60 kg were included in the sensitivity analysis.
After 10 years of followup the discounted total direct medical costs per patient
were U$55,998 (54,35457,776) for MTX, U$99,888 (94,694104,437) for abatacept,
and $79,174 (75,79583,899)for infliximab. The total number of QALYs gained (dis-
counted) by MTX, abatacept, and infliximab were: 2.88 (2.792.95), 3.94 (3.794.09)
and 3.17 (3.093.27) respectively. The calculated ICERs for abatacept and infliximab
compared to MTX were U$ 37,513 (35,22139,909) and U$75,873 (62,825103,132)
per QALY gained, respectively. CONCLUSIONS: In patients with RA  IR MTX in
Colombia, the use of abatacept is more cost-effective than the use of infliximab,
both compared to MTX.
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OBJECTIVES: To conduct a structured review of the recent osteoporosis cost-effec-
tiveness modeling literature and provide an overview of their methodologies and
approaches.METHODS:A detailed systematic reviewwas performed of the follow-
ing literature databases: MEDLINE, MEDLINE In-Process, EMBASE, Cochrane, HEED,
NHSEED, EconLit, and googlescholar. Using pre-selected inclusion/exclusion crite-
ria relevant studies published since January 2005 were identified. Relevant infor-
mation fromeach identified studywas extracted according to a predefined grid and
essential features of each osteoporosis cost-effectiveness model were recorded.
RESULTS: Forty-eight relevant and recently published osteoporosis cost-effective-
ness models were identified. Model structures were cohort Markov (56%) and indi-
vidualized microsimulations (44%). Most models (35) used a lifetime timeframe
(i.e., death or age 100). The primary interventions investigated were bisphospho-
nates (79%), raloxefine (15%), and hormone replacement therapy (10%). In 98% of
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